Mersana Therapeutics Announces Poster Presentations Demonstrating Differentiating Aspects of ADC Platform Technology at the A...
April 09 2018 - 8:00AM
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody drug conjugates (ADCs) based on its
Dolaflexin® and other proprietary platforms, today announced that
company scientists are presenting data on Mersana’s lead ADC
platform and its unique Dolalock technology at the 2018 American
Association for Cancer Research (AACR) Annual Meeting being held
April 14-18 at the McCormick Place in Chicago, IL. In addition, the
Company co-authored a poster that will be presented by its partner,
Takeda, demonstrating that XMT-1522 (TAK-522) showed significant
inhibition of tumor growth in combination with an anti-PD1 antibody
in preclinical breast cancer models. Details of the poster sessions
are as follows:
Poster Title: Unique
pharmacologic properties of Dolaflexin-based ADCs – a controlled
bystander effectSession: Antibody-Drug
Conjugates: Agents and TechnologiesSession Date and
Time: April 15, 2018, 1:00 – 5:00 P.M.
(CST)Location: McCormick Place South, Exhibit
Hall A, Poster Section 35Poster Board
Number: 754/21
Poster Title: Synergy of
an anti-HER2 ADC TAK-522 (XMT-1522) in combination with anti-PD1
monoclonal antibody (mAb) in a syngeneic breast cancer model
expressing human HER2Session: Late-Breaking
Research: Immunology 2Session Date and
Time: Tuesday Apr 17, 2018 1:00 PM - 5:00 PM
(CST)Location: McCormick Place South, Exhibit
Hall A, Poster Section 44Poster Board
Number: LB 294/16
About XMT-1522 XMT-1522 is a
Dolaflexin ADC targeting HER2-expressing tumors. XMT-1522 comprises
a novel, proprietary HER2 antibody which is conjugated with
Mersana’s Dolaflexin platform – a Fleximer polymer linked with a
proprietary auristatin payload. XMT-1522 provides a drug load of
approximately 12 molecules per antibody, specifically designed to
improve potency while simultaneously increasing tolerability.
XMT-1522 has the potential to extend HER2-targeted therapy beyond
the current “HER2-positive” populations into patients with lower
levels of HER2 expression. The Phase 1 protocol will evaluate
XMT-1522 in patients with advanced HER2-positive breast and gastric
cancer, as well as advanced breast cancer with low HER2 expression
and non-small cell lung cancer. Mersana received FDA clearance of
its Investigational New Drug application for XMT-1522 in October
2017. More information can be found on the ongoing Phase 1 clinical
study at clinicaltrials.gov.
About Dolaflexin The Dolaflexin
platform is designed to increase the efficacy, safety and
tolerability of ADCs by overcoming key limitations of existing
technologies based on direct conjugation of a payload molecule to
an antibody. Dolaflexin consists of Fleximer, a biodegradable,
highly biocompatible, water soluble polymer, to which are attached
multiple molecules of our proprietary auristatin drug payload,
using a linker specifically optimized for use with our polymer. The
high-water solubility of the Fleximer polymer compensates for the
low solubility of the payload, surrounding the payload and
protecting it from aggregation and maintaining stability in
circulation. Multiple molecules of this Dolaflexin polymer-drug
conjugate can then be attached to an antibody of choice, which
significantly increases the payload capacity of the resulting ADC.
This approach differs from most other ADC technologies where the
payload is directly conjugated to the antibody via a linker. Using
its Dolaflexin platform, Mersana has been able to generate ADCs
with Drug-to-Antibody Ratio (DAR) between 12 to 15 while
maintaining acceptable pharmacokinetics and drug-like properties in
animal models. This represents a three to four-fold increase in DAR
relative to traditional ADC approaches.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company
using its differentiated and proprietary ADC platforms to develop
highly targeted drugs with increased tolerability and expanded
opportunities to deliver meaningful clinical benefit to
patients. Mersana’s product candidate XMT-1522 is in Phase 1
clinical trials in patients with advanced tumors expressing HER2,
including breast cancer, non-small-cell-lung-cancer (NSCLC) and
gastric cancer patients. The Company’s second product
candidate, XMT-1536, is in Phase 1 clinical trials in patients with
tumors expressing NaPi2b, including ovarian cancer, NSCLC and other
cancers. In addition, multiple partners are using Mersana’s
platform to advance their ADC pipelines.
Media ContactPaul Kidwell
paulkidwell@comcast.net 617-680-1088
Investors ContactStern Investor Relations,
Inc.Christina Tartagliachristina@sternir.com(212) 362-1200
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Sep 2023 to Sep 2024